Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Rhea-AI Summary

Guardant Health, Inc. announces successful results from the ECLIPSE study showing the effectiveness of its Shield blood test in detecting colorectal cancer. The study reveals 83% sensitivity in detecting individuals with CRC and 88% sensitivity in detecting Stages I-III. Shield's potential FDA approval could revolutionize CRC screening, offering a convenient and accurate alternative to traditional methods.

Insights

Oncology Doctor

The recent findings from the ECLIPSE study represent a significant advancement in the field of oncology, particularly in the early detection of colorectal cancer (CRC). The study's reported 83% sensitivity in detecting CRC and 90% specificity are notable because early-stage detection is crucial for improving patient outcomes. The high sensitivity rates for Stages II and III, both at 100%, are particularly encouraging, as these stages are often when CRC is most treatable. However, the lower sensitivity for Stage I, at 65% for pathology-confirmed and 55% for clinical Stage I, suggests there is still room for improvement in detecting the earliest stages of CRC.

From a clinical perspective, the potential FDA approval and subsequent Medicare coverage of the Shield blood test could lead to increased screening adherence, given the non-invasiveness and convenience compared to traditional methods like colonoscopy. This shift could ultimately result in earlier diagnoses and better survival rates, as the 5-year relative survival rate for early-stage colon cancer is significantly higher than that of advanced stages. The test's ability to detect circulating tumor DNA (ctDNA) is a testament to the advancements in precision medicine and the move towards more patient-friendly screening modalities.

Market Research Analyst

Guardant Health's Shield test has the potential to disrupt the CRC screening market by offering a more accessible and less invasive alternative to current methods. The test's high adherence rate in real-world settings and the ability to triple screening rates among previously non-compliant adults are particularly promising for the company's market penetration and growth. The market impact could be substantial, not only for Guardant Health but also for competitors, as it may set a new standard for CRC screening practices.

Investors should monitor the FDA's decision on Shield's premarket approval application closely, as approval could lead to significant revenue growth for Guardant Health. Additionally, the test's alignment with the increasing preference for non-invasive medical procedures could position the company favorably within the precision oncology sector. It's important to note, however, that market adoption rates and the impact on Guardant Health's financials will depend on factors such as insurance coverage, pricing strategy and the ability to maintain high sensitivity and specificity in a broader population.

Health Economist

The introduction of the Shield blood test could have profound implications for healthcare economics, particularly in the realm of preventative care for colorectal cancer. The potential for Medicare coverage is a critical factor in ensuring widespread access and could lead to cost savings by reducing the number of advanced-stage CRC cases that are more expensive to treat. Moreover, the test's convenience could lead to increased compliance with screening guidelines, which is cost-effective in the long run by catching cancers earlier when they are less costly to manage.

However, it is essential to consider the cost-effectiveness of the Shield test compared to existing screening methods. While non-invasive, if the cost per test is significantly higher, it could offset the savings from increased early detection. Furthermore, the economic impact will also depend on the test's adoption by healthcare providers and whether it can truly replace or complement current screening protocols. Long-term studies on health outcomes and cost implications will be crucial to assess the full economic impact of incorporating Shield into standard CRC screening practices.

• Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90%
• Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its Shield^TM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.

Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk. (Photo: Business Wire)

“Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO. “We believe the publication of the ECLIPSE study in The New England Journal of Medicine, one of the world’s leading medical journals, is an endorsement of the quality of our clinical data and the potential value of the Shield test. We are confident that offering an accurate blood test has the potential to significantly reduce preventable colorectal cancer deaths.”

One of the largest studies of its kind, ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode) is a 20,000+-patient registrational study to evaluate the performance of Shield compared to a screening colonoscopy. The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).

Highlights of the study results to be published in The New England Journal of Medicine* show that Shield demonstrated:

• 83% sensitivity in detecting individuals with CRC
• 88% sensitivity in detecting pathology-confirmed Stages I-III
• Sensitivity by stage of:
  • 65% for pathology-confirmed Stage I; 55% for clinical Stage I
  • 100% for Stage II
  • 100% for Stage III
  • 100% for Stage IV

These results are on par with the performance of other guideline-recommended non-invasive screening modalities, where overall sensitivity in detecting colorectal cancer ranges from 74% to 92%.¹

“More than 3 out of 4 Americans who die from colorectal cancer are not up to date with their recommended screening,² highlighting the need for a more convenient and less invasive screening method that can overcome barriers associated with traditional options,” said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. “The ECLIPSE study results published today support the use of a blood test as a screening option that could help overcome these barriers and improve CRC screening rates."

Publication of ECLIPSE follows Guardant Health’s submission of its premarket approval (PMA) application to the U. S. Food and Drug Administration (FDA) for Shield, which included key data points from the study. Since the launch of the lab-developed version of the Shield test in May 2022, it has been used by more than 20,000 people and more than 90% of patients who were prescribed the test in the real-world clinical setting completed it. One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield. The test’s sensitivity in detecting CRC, combined with this real-world adherence, suggests that Shield has the potential to detect more CRCs at a curable stage than traditional screening methods.^3,4,5,6

“Colorectal cancer is highly treatable if caught in the early stages, yet more than 50 million people in the U.S. are still not completing their recommended screening with the methods available today,” said Chris Evans, president of the Colon Cancer Coalition. “This publication gets us one step closer to having an additional option to offer patients – one that is both convenient and accessible—and will help us close the screening gap.”

Colorectal cancer is the second-leading cause of cancer deaths in the U.S. The American Cancer Society estimates that more than 150,000 people will be diagnosed with CRC in 2024⁷ and it is expected to become the leading cause of cancer-related deaths by 2030 in adults aged 20-49.⁸ More than 75% of people who die from CRC are not up to date with recommended screening,⁹ often due to the perception that current methods such as colonoscopy or stool-based tests are invasive, time-consuming and inconvenient. Early detection, however, is crucial. When colon cancer is found at an early stage before it has spread, the 5-year relative survival rate is 91%. If the cancer has spread to distant parts of the body, the 5-year survival rate is 13%.

“The results of the study are a promising step toward developing more convenient tools to detect colorectal cancer early while it is more easily treated,” said corresponding author William M. Grady, MD, a gastroenterologist at Fred Hutchinson Cancer Center. “The test, which has an accuracy rate for colon cancer detection similar to stool tests used for early detection of cancer, could offer an alternative for patients who may otherwise decline current screening options."

* Representatives of the media who are not able to access the article content can contact press@guardanthealth.com.

About the ECLIPSE study

ECLIPSE is a prospective registrational study to evaluate the performance of Guardant Health’s blood test in detecting signs of CRC compared to a screening colonoscopy in average-risk adults between the ages of 45 and 84 from across the U.S. The ECLIPSE study included more than 200 clinical trial sites in rural and urban communities across 34 states. Study data includes 12% Black, 13% Hispanic and 7% Asian American populations. Enrollment among Black Americans was above average for a clinical trial, which is important given the disproportionate impact of CRC on the Black community.¹⁰

About Shield

The Shield test for colorectal cancer screening is commercially available for eligible individuals by prescription only through healthcare professionals. This LDT (Laboratory Developed Test) is intended to be complementary to, and not a replacement for, current recommended CRC screening methods. A negative result does not rule out the presence of cancer. Patients with an abnormal blood-based screening result should be referred for a diagnostic colonoscopic evaluation.

More information about the Shield test is available at bloodbasedscreening.com.

About Guardant Health

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Disclosures

Dr. Chung and Dr. Grady are paid members of Guardant Health’s ECLIPSE Steering Committee. Both advised on the design and procedure of the clinical study and data analysis.

References

1. Chung, D., et al. Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population. Abstract #3910067. Digestive Disease Week 2023; May 6-9, 2023; Chicago, IL.
2. Gastroenterology. 2019 Jan; 156(1): 63–74.e6. www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=30268788. Accessed March 6, 2024.
3. Bretthauer M, Løberg M, Wieszczy P, et al.; NordICC Study Group. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547-1556.
4. Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer screening: An updated decision analysis for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2021a. Report No.: 202s.
5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Eng J Med. 2014.
6. Coronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. Epub ahead of print:23 January 2024. doi:10.1136/gutjnl-2023-330980.
7. American Cancer Society: Colorectal Cancer Key Statistics. www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html Accessed online Feb 5, 2021.
8. Colorectal Cancer Alliance. https://colorectalcancer.org/resources-support/community-support/young-onset-support/young-onset-crc-facts. Accessed March 13, 2024.
9. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology 2019;156:63–74.
10. U.S. Food & Drug Administration. 2022 Drug Trials Snapshots Summary Report. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots. Accessed December 18, 2023.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313547689/en/

Investor Contact:

investors@guardanthealth.com

Media Contact:

Michael Weist

press@guardanthealth.com

+1 650-647-3643

Source: Guardant Health, Inc.

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Guardant Health, Inc. with the ticker symbol GH.

What is the sensitivity rate of Shield in detecting individuals with colorectal cancer?

Shield demonstrated an 83% sensitivity rate in detecting individuals with colorectal cancer.

What is the sensitivity rate of Shield in detecting Stages I-III colorectal cancer?

Shield showed an 88% sensitivity rate in detecting pathology-confirmed Stages I-III colorectal cancer.

What is the potential significance of the Shield blood test for colorectal cancer screening?

The Shield blood test has the potential to significantly reduce preventable colorectal cancer deaths by offering a convenient and accurate screening method.

What is the expected impact of Shield on CRC screening rates?

Shield has the potential to help overcome barriers associated with traditional screening methods and improve CRC screening rates.